Quoin Pharmaceuticals’ Public Offering Raises Concerns about Company’s Financial Health
ASHBURN, Va. March 05, 2024 - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the pricing of its public offering, raising approximately $6.5 million in gross proceeds. However, the financial performance of the specialty pharmaceutical company raises concerns about its long-term viability.
Quoin Pharmaceuticals, focused on rare and orphan diseases, faces significant challenges as it recorded a cumulative net loss of $-16 million in the 12 months ending in the third quarter of 2023. This resulted in a negative return on investment (ROI) of -134.02%, which is alarming. Furthermore, within the healthcare sector, 823 other companies demonstrated a higher return on investment, indicating Quoin’s underperformance compared to its peers.
The pricing of the public offering, which involved 4,062,500 ordinary shares represented by American Depositary Shares (ADS), as well as Series D and Series E warrants, was set at $1.60 per ADS. While attracting investment, the offering’s relatively small size raises questions about the company’s ability to address its financial challenges effectively.
The Series D and Series E warrants, exercisable immediately following issuance, have an exercise price of $1.60 per share and expiration periods of two and five years, respectively. With these warrants in place, investors could potentially reap additional benefits, but this depends on the company’s ability to turn its financial performance around.
Quoin Pharmaceuticals’ overall return on investment has witnessed a slight improvement, moving from a total ROI ranking of 5087 in the second quarter of 2023 to 4267 in the third quarter of the same year. Despite this progress, the company still lags significantly behind other healthcare sector players.
The financial health of Quoin Pharmaceuticals remains a concern, as its negative ROI and inferior performance compared to its peers raise doubts about its future prospects. It is crucial for investors to carefully evaluate the risks before considering participation in the public offering.
Comments